Mice in ecstasy: Advanced animal models in the study of MDMA

Current Pharmaceutical Biotechnology

Volumn 11, Issue 5, 2010, Pages 421-433

  Stove, Christophe P ^a   de Letter, Els A ^a   Piette, Michel H A ^a   Lambert, Willy E ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

3,4 methylenedioxymethamphetamine; Ecstasy; Knock out; MDMA; Mouse models; Review; Transgenic

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ALPHA 2A ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CYTOCHROME P450 2D6; DOPAMINE; DOPAMINE RECEPTOR; ENKEPHALIN; MU OPIATE RECEPTOR; NALOXONE; NEURONAL NITRIC OXIDE SYNTHASE; NORADRENALIN; OREXIN; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BRAIN; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; COGNITION; DNA MODIFICATION; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG METABOLISM; HEART RATE; HYPERACTIVITY; HYPERTHERMIA; KNOCKOUT MOUSE; LOCOMOTION; MOUSE; NARCOLEPSY; NERVE CELL PLASTICITY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REINFORCEMENT; REWARD; SEROTONINERGIC SYSTEM; SLEEP DISORDER; TACHYCARDIA; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; HALLUCINOGENS; HUMANS; MICE; MICE, TRANSGENIC; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; SPECIES SPECIFICITY;

ANIMALIA; MUS; RATTUS;

EID: 77956593988     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110791591508     Document Type: Article

References (137)

1. Pentney, A. R. An exploration of the history and controversies surrounding MDMA and MDA. J. Psychoactive Drugs, 2001, 33(3), 213-221.
2. Vogels, N.; Brunt, T. M.; Rigter, S.; van Dijk, P.; Vervaeke, H.; Niesink, R. J. M. Content of ecstasy in the Netherlands: 1993-2008. Addiction, 2009, 104(12), 2057-2066.
3. Baylen, C.A.; Rosenberg, H. A review of the acute subjective effects of MDMA/ecstasy. Addiction, 2006, 101(7), 933-947.
4. Greer, G.; Strassman, R. J. Information on Ecstasy. Am. J. Psychiatry, 1985, 142(11), 1391.
5. Murphy, D. L.; Lesch, K. P. Targeting the murine serotonin transporter: insights into human neurobiology. Nat. Rev. Neurosci., 2008, 9(2), 85-96.
6. Schmidt, C. J.; Taylor, V. L. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors. Eur. J. Pharmacol., 1990, 181(1-2), 133-136.
7. Sanchez, V.; Camarero, J.; Esteban, B.; Peter, M. J.; Green, A. R.; Colado, M. I. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br. J. Pharmacol., 2001, 134(1), 46-57.
8. Capela, J. P.; Carmo, H.; Remiao, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. Molecular and cellular mechanisms of ecstasy-neurotoxicity: an overview. Mol. Neurobiol., 2009, 39(3), 210-271.
9. Bankson, M.G.; Cunningham, K.A. 3,4-methylenedioxy-methamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J. Pharmacol. Exp. Ther., 2001, 297(3), 846-852.
10. Green, A. R.; Cross, A. J.; Goodwin, G. M. Review of the pharmacology and clinical-pharmacology of 3,4-methylenedioxy-methamphetamine (MDMA or ecstasy). Psychopharmacology, 1995, 119(3), 247-260.
11. Battaglia, G.; Brooks, B. P.; Kulsakdinun, C.; Desouza, E. B. Pharmacologic profile of mdma (3,4-methylenedioxy-methamphetamine) at various brain recognition sites. Eur. J. Pharmacol., 1988, 149(1-2), 159-163.
12. Peters, G. J. Y.; Kok, G. A structured review of reasons for ecstasy use and related behaviours: pointers for future research. BMC Public Health, 2009, 9, 230.
13. Peters, G. J. Y.; Kok, G.; Abraham, C. Social cognitive determinants of ecstasy use to target in evidence-based interventions: a meta-analytical review. Addiction, 2008, 103(1), 109-118.
14. Peters, G. J. Y.; Kok, G.; Schaalma, H. P. Careers in ecstasy use: do ecstasy users cease of their own accord? Implications for intervention development. BMC Public Health, 2008, 8, 376.
15. Riley, S. C.; James, C.; Gregory, D.; Dingle, H.; Cadger, M. Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction, 2001, 96(7), 1035-1047.
16. Gross, S. R.; Barrett, S. P.; Shestowsky, J. S.; Pihl, R. O. Ecstasy and drug consumption patterns: a Canadian rave population study. Can. J. Psychiatry, 2002, 47(6), 546-551.
17. Barrett, S. P.; Darredeau, C.; Pihl, R. O. Patterns of simultaneous polysubstance use in drug using university students. Hum. Psychopharm. Clin., 2006, 21(4), 255-263.
18. Barrett, S. P.; Gross, S. R.; Garand, I.; Pihl, R. O. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst. Use Misuse, 2005, 40(9-10), 1525-1537.
19. Uys, J. D.; Niesink, R. J. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature. Drug Alcohol Rev., 2005, 24(4), 359-368.
20. Gouzoulis-Mayfrank, E.; Daumann, J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J. Psychopharmacol., 2006, 20(2), 188-193.
21. Nutt, D. J. Equasy--an overlooked addiction with implications for the current debate on drug harms. J. Psychopharmacol., 2009, 23(1), 3-5.
22. Parrott, A. C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J. Psychopharmacol., 2005, 19(1), 71-83.
23. de la Torre, R.; Farre, M.; Roset, P. N.; Pizarro, N.; Abanades, S.; Segura, M.; Segura, J.; Cami, J. Human pharmacology of MDMA - Pharmacokinetics, metabolism, and disposition. Ther. Drug Monit., 2004, 26(2), 137-144.
24. de la Torre, R.; Farre, M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci., 2004, 25(10), 505-508.
25. Han, D. D.; Gu, H. H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol., 2006, 6, 6.
26. Rothman, R. B.; Baumann, M. H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol., 2003, 479(1-3), 23-40.
27. Koch, S.; Galloway, M. P. MDMA induced dopamine release in vivo: Role of endogenous serotonin. J. Neural Transm., 1997, 104(2-3), 135-146.
28. Hall, A. P.; Henry, J. A. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Brit. J. Anaesth., 2006, 96(6), 678-685.
29. Green, A. R.; Mechan, A. O.; Elliott, J. M.; O'Shea, E.; Colado, M. I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol. Rev., 2003, 55(3), 463-508.
30. McCann, U. D.; Ricaurte, G. A. Amphetamine neurotoxicity: accomplishments and remaining challenges. Neurosci. Biobehav. Rev., 2004, 27(8), 821-826.
31. Tucker, G. T.; Lennard, M. S.; Ellis, S. W.; Woods, H. F.; Cho, A. K.; Lin, L. Y.; Hiratsuka, A.; Schmitz, D. A.; Chu, T. Y. Y. The Demethylenation of Methylenedioxymethamphetamine (Ecstasy) by Debrisoquine Hydroxylase (Cyp2D6). Biochem. Pharmacol., 1994, 47(7), 1151-1156.
32. Colado, M. I.; Williams, J. L.; Green, A. R. The hyperthermic and neurotoxic effects of ecstasy (Mdma) and 3,4-methylene-dioxyamphetamine (Mda) in the dark-agouti (Da) rat, a Model of the Cyp2D6 poor metabolizer phenotype. Brit. J. Pharmacol., 1995, 115(7), 1281-1289.
33. Farre, M.; de la Torre, R.; Mathuna, B. O.; Roset, P. N.; Peiro, A. M.; Torrens, M.; Ortuno, J.; Pujadas, M.; Cami, J. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology, 2004, 173(3-4), 364-375.
34. de la Torre, R.; Farre, M.; Ortuno, J.; Mas, M.; Brenneisen, R.; Roset, P. N.; Segura, J.; Cami, J. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol., 2000, 49(2), 104-109.
35. Gilhooly, T. C.; Daly, A. K. CYP2D6 deficiency, a factor in ecstasy related deaths? Br. J. Clin. Pharmacol., 2002, 54(1), 69-70.
36. O'Donohoe, A.; O'Flynn, K.; Shields, K.; Hawi, Z.; Gill, M. MDMA toxicity: No evidence for a major influence of metabolic genotype at CYP2D6. Addict. Biol., 1998, 3(3), 309-314.
37. Schwab, M.; Seyringer, E.; Brauer, R. B.; Hellinger, A.; Griese, E. U. Fatal MDMA intoxication. Lancet, 1999, 353(9152), 593-594.
38. Carmo, H.; Brulport, M.; Hermes, M.; Oesch, F.; Silva, R.; Ferreira, L. M.; Branco, P. S.; de Boer, D.; Remiao, F.; Carvalho, F.; Schon, M. R.; Krebsfaenger, N.; Doehmer, J.; Bastos, M. D.; Hengstler, J. G. Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine ('ecstasy') cytotoxicity. Pharmacogenet. Genomics, 2006, 16(11), 789-799.
39. Krebsfaenger, N.; Murdter, T. E.; Zanger, U. M.; Eichelbaum, M. F.; Doehmer, J. V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans. Altex, 2003, 20(3), 143-154.
40. Stanley, L. A.; Horsburgh, B. C.; Ross, J.; Scheer, N.; Wolf, C. R. Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior. Drug Metab. Rev., 2009, 41(1), 27-65.
41. Mann, H.; Ladenheim, B.; Hirata, H.; Moran, T. H.; Cadet, J. L. Differential toxic effects of methamphetamine (METH) and methy-lenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res., 1997, 769(2), 340-346.
42. Upreti, V. V.; Eddington, N. D. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. J. Pharm. Sci., 2008, 97(4), 1593-1605.
43. Scheidweiler, K. B.; Ladenheim, B.; Cadet, J. L.; Huestis, M. A. Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. Neurotox. Res., 2009, doi: 10.1007/s12640-009-9124-z.
44. Scearce-Levie, K.; Chen, J. P.; Gardner, E.; Hen, R. 5-HT receptor knockout mice: Pharmacological tools or models of psychiatric disorders. Ann. N. Y. Acad. Sci., 1999, 868, 701-715.
45. Scearce-Levie, K.; Viswanathan, S. S.; Hen, R. Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology, 1999, 141(2), 154-161.
46. Doly, S.; Valjent, E.; Setola, V.; Callebert, J.; Herve, D.; Launay, J. M.; Maroteaux, L. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neurosci., 2008, 28(11), 2933-2940.
47. Bengel, D.; Murphy, D. L.; Andrews, A. M.; Wichems, C. H.; Feltner, D.; Heils, A.; Mossner, R.; Westphal, H.; Lesch, K. P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (ecstasy) in serotonin transporter-deficient mice. Mol. Pharmacol., 1998, 53(4), 649-655.
48. Muller, C. P.; Carey, R. J.; Huston, J. P.; Silva, M. A. D. Serotonin and psychostimulant addiction: Focus on 5-HT1A-receptors. Prog. Neurobiol., 2007, 81(3), 133-178.
49. Fletcher, P. J.; Korth, K. M.; Robinson, S. R.; Baker, G. B. Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. Psychopharmacology, 2002, 162(3), 282-291.
50. Trigo, J. M.; Renoir, T.; Lanfumey, L.; Hamon, M.; Lesch, K. P.; Robledo, P.; Maldonado, R. 3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice. Biol. Psychiatry, 2007, 62(6), 669-679.
51. Rudnick, G.; Wall, S. C. Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol. Pharmacol., 1993, 43(2), 271-276.
52. Compan, V.; Scearce-Levie, K.; Crosson, C.; Daszuta, A.; Hen, R. Enkephalin contributes to the locomotor stimulating effects of 3,4-methylenedioxy-N-methylamphetamine. Eur. J. Neurosci., 2003, 18(2), 383-390.
53. Aso, E.; Renoir, T.; Mengod, G.; Ledent, C.; Hamon, M.; Maldonado, R.; Lanfumey, L.; Valverde, O. Lack of CB1 receptor activity impairs serotonergic negative feedback. J. Neurochem., 2009, 109(3), 935-944.
54. Okuda, T.; Zhang, D. Y.; Shao, H.; Okamura, N.; Takino, N.; Iwamura, T.; Sakurai, E.; Yoshikawa, T.; Yanai, K. Methamphetamine- and 3,4-Methylenedioxymethamphetamine-induced behavioral changes in histamine H-3-receptor knockout mice. J. Pharmacol. Sci., 2009, 111(2), 167-174.
55. Doly, S.; Bertran-Gonzalez, J.; Callebert, J.; Bruneau, A.; Banas, S. M.; Belmer, A.; Boutourlinsky, K.; Herve, D.; Launay, J. M.; Maroteaux, L. Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice. PLoS One, 2009, 4(11), e7952.
56. Itzhak, Y.; Anderson, K. L.; Ali, S. F. Differential response of nNOS knockout mice to MDMA (ecstasy)- and methamphetamine-induced psychomotor sensitization and neurotoxicity. Ann. N. Y. Acad. Sci., 2004, 1025, 119-128.
57. Risbrough, V. B.; Masten, V. L.; Caldwell, S.; Paulus, M. P.; Low, M. J.; Geyer, M. A. Differential contributions of dopamine D-1, D-2, and D-3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology, 2006, 31(11), 2349-2358.
58. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 1996, 379(6566), 606-612.
59. Gainetdinov, R. R.; Jones, S. R.; Caron, M. G. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry, 1999, 46(3), 303-311.
60. Ralph, R. J.; Paulus, M. P.; Fumagalli, F.; Caron, M. G.; Geyer, M. A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: Differential effects of D1 and D2 receptor antagonists. J. Neurosci., 2001, 21(1), 305-313.
61. Powell, S. B.; Lehmann-Masten, V. D.; Paulus, M. P.; Gainetdinov, R. R.; Caron, M. G.; Geyer, M. A. MDMA ecstasy alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology, 2004, 173(3-4), 310-317.
62. Sotnikova, T. D.; Beaulieu, J. M.; Barak, L. S.; Wetsel, W. C.; Caron, M. G.; Gainetdinov, R. R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol., 2005, 3(8), e271.
63. Schmidt, W. J.; Mayerhofer, A.; Meyer, A.; Kovar, K. A. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci. Lett., 2002, 330(3), 251-254.
64. Renoir, T.; Paizanis, E.; Yacoubi, M.; Saurini, F.; Hanoun, N.; Melfort, M.; Lesch, K. P.; Hamon, M.; Lanfumey, L. Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. Int. J. Neuropsychopharmacol., 2008, 11(8), 1149-1162.
65. Banasr, M.; Hery, M.; Printemps, R.; Daszuta, A. Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology, 2004, 29(3), 450-460.
66. O'Leary, O. F.; Bechtholt, A. J.; Crowley, J. J.; Hill, T. E.; Page, M. E.; Lucki, I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology, 2007, 192(3), 357-371.
67. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; Belzung, C.; Hen, R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science, 2003, 301(5634), 805-809.
68. Thompson, M. R.; Li, K. M.; Clemens, K. J.; Gurtman, C. G.; Hunt, G. E.; Cornish, J. L.; McGregor, I. S. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology, 2004, 29(4), 694-704.
69. Xie, T.; Tong, L. Q.; McCann, U. D.; Yuan, J.; Becker, K. G.; Mechan, A. O.; Cheadle, C.; Donovan, D. M.; Ricaurte, G. A. Identification and characterization of metallothionein-1 and-2 gene expression in the context of (+/-)3,4-methylenedioxy-methamphetamine-induced toxicity to brain dopaminergic neurons. J. Neurosci., 2004, 24(32), 7043-7050.
70. Pedersen, M. O.; Jensen, R.; Pedersen, D. S.; Skjolding, A. D.; Hempel, C.; Maretty, L.; Penkowa, M. Met-aletal/et-allothionein-I plus II in neuroprotection. Biofactors, 2009, 35(4), 315-325.
71. Bell, S. G.; Vallee, B. L. The metallothionein/thionein system: An oxidoreductive metabolic zinc link. Chembiochem., 2009, 10(1), 55-62.
72. Itzhak, Y.; Achat-Mendes, C. Methamphetamine and MDMA (ecstasy) neurotoxicity: 'of mice and men'. IUBMB Life, 2004, 56(5), 249-255.
73. Cadet, J. L.; Ladenheim, B.; Baum, I.; Carlson, E.; Epstein, C. Cuzn superoxide-dismutase (Cuznsod) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (Mda) and of methylenedioxymethamphetamine (Mdma). Brain Res., 1994, 655(1-2), 259-262.
74. Cadet, J. L.; Ladenheim, B.; Hirata, H.; Rothman, R. B.; Ali, S.; Carlson, E.; Epstein, C.; Moran, T. H. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (Mdma) - evidence from using cuzn-Superoxide dismutase transgenic mice. Synapse, 1995, 21(2), 169-176.
75. Jayanthi, S.; Ladenheim, B.; Andrews, A. M.; Cadet, J. L. Overexpression of human copper zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxy-methamphetamine (ecstasy). Neuroscience, 1999, 91(4), 1379-1387.
76. Colado, M. I.; O'Shea, E.; Esteban, B.; Granados, R.; Green, A. R. In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology, 1999, 38(2), 307-314.
77. Colado, M. I.; OShea, E.; Granados, R.; Murray, T. K.; Green, A. R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol., 1997, 121(5), 889-900.
78. Itzhak, Y.; Gandia, C.; Huang, P. L.; Ali, S. F. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J. Pharmacol. Exp. Ther., 1998, 284(3), 1040-1047.
79. Tipton, K. F.; Boyce, S.; O'Sullivan, J.; Davey, G. P.; Healy, J. Monoamine oxidases: certainties and uncertainties. Curr. Med. Chem., 2004, 11(15), 1965-1982.
80. Grimsby, J.; Toth, M.; Chen, K.; Kumazawa, T.; Klaidman, L.; Adams, J. D.; Karoum, F.; Gal, J.; Shih, J. C. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat. Genet., 1997, 17(2), 206-210.
81. Fornai, F.; Chen, K.; Giorgi, F. S.; Gesi, M.; Alessandri, M. G.; Shih, J. C. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. J. Neurochem., 1999, 73(6), 2434-2440.
82. Fornai, F.; Giorgi, F. S.; Gesi, M.; Chen, K.; Alessandri, M. G.; Shih, J. C. Biochemical effects of the monoamine neurotoxins DSP-4 and MDMA in specific brain regions of MAO-B-deficient mice. Synapse, 2001, 39(3), 213-221.
83. Leonardi, E. T. K.; Azmitia, E. C. Mdma (ecstasy) inhibition of mao type-a and type-B - comparisons with fenfluramine and fluoxetine (prozac). Neuropsychopharmacol., 1994, 10(4), 231-238.
84. Gordon, C. J. Thermophysiological responses to hyperthermic drugs: extrapolating from rodent to human. Prog. Brain Res., 2007, 162, 63-79.
85. Malberg, J. E.; Seiden, L. S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci., 1998, 18(13), 5086-5094.
86. Miller, D. B.; Ocallaghan, J. P. Environment-induced, drug-induced and stress-induced alterations in body-temperature affect the neurotoxicity of substituted Amphetamines in the C57Bl/6J Mouse. J. Pharmacol. Exp. Ther., 1994, 270(2), 752-760.
87. Touriño, C.; Ledent, C.; Maldonado, R.; Valverde, O. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement. Biol. Psychiatry, 2008, 63(11), 1030-1038.
88. Lavelle, A.; Honner, V.; Docherty, J. R. Investigation of the prejunctional alpha(2)-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br. J. Pharmacol., 1999, 128(5), 975-980.
89. McDaid, J.; Docherty, J. R. Vascular actions of MDMA involve alpha(1) and alpha(2)-adrenoceptors in the anaesthetized rat. Br. J. Pharmacol., 2001, 133(3), 429-437.
90. Bexis, S.; Docherty, J. R. Role of alpha(2A)-adrenoceptors in the effects of MDMA on body temperature in the mouse. Br. J. Pharmacol., 2005, 146(1), 1-6.
91. Mills, E. M.; Rusyniak, D. E.; Sprague, J. E. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med., 2004, 82(12), 787-799.
92. Mills, E. M.; Banks, M. L.; Sprague, J. E.; Finkel, T. Pharmacology: uncoupling the agony from ecstasy - a mitochondrial protein may mediate a dangerous side-effect of some recreational drugs. Nature, 2003, 426(6965), 403-404.
93. McCardle, K.; Luebbers, S.; Carter, J. D.; Croft, R. J.; Stough, C. Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology, 2004, 173(3-4), 434-439.
94. Wareing, M.; Fisk, J. E.; Montgornery, C.; Murphy, P. N.; Chandler, M. D. Information processing speed in ecstasy (MDMA) users. Hum. Psychopharmacol., 2007, 22(2), 81-88.
95. Zakzanis, K. K.; Campbell, Z.; Jovanovski, D. The neuropsychology of ecstasy (MDMA) use: A quantitative review. Hum. Psychopharmacol., 2007, 22(7), 427-435.
96. Ward, J.; Hall, K.; Haslam, C. Patterns of memory dysfunction in current and 2-year abstinent MDMA users. J. Clin. Exp. Neuropsychol., 2006, 28(3), 306-324.
97. Nawata, Y.; Hiranita, T.; Yamamoto, T. A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy). Neuropsychopharmacol., 2010, 35(2), 515-520.
98. Morley, K. C.; Gallate, J. E.; Hunt, G. E.; Mallet, P. E.; McGregor, I. S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (Ecstasy). Eur. J. Pharmacol., 2001, 433(1), 91-99.
99. McGregor, I. S.; Gurtman, C. G.; Morley, K. C.; Clemens, K. J.; Blokland, A.; Li, K. M.; Cornish, J. L.; Hunt, G. E. Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology, 2003, 168(4), 465-474.
100. Piper, B. J.; Meyer, J. S. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol. Biochem. Behav., 2004, 79(4), 723-731.
101. Callaway, C. W.; Wing, L. L.; Geyer, M. A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther., 1990, 254(2), 456-464.
102. Kindlundh-Hogberg, A. M. S.; Zhang, X. Q.; Svenningsson, P. S100B overexpressing mutant mice exhibit prolonged behavioural and biochemical responses towards repeated intermittent binge treatments with MDMA. Int. J. Neuropsychopharmacol., 2009, 12(2), 201-215.
103. Dulawa, S. C.; Hen, R.; Scearce-Levine, K.; Geyer, M. A. 5-HT1B receptor modulation of prepulse inhibition: Recent findings in wild-tppe and 5HT(1B) knockout mice. Ann. N Y Acad. Sci., 1998, 861, 79-84.
104. Swerdlow, N. R.; Weber, M.; Qu, Y.; Light, G. A.; Braff, D. L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology, 2008, 199(3), 331-388.
105. Dulawa, S. C.; Scearce-Levie, K. A.; Hen, R.; Geyer, M. A. Serotonin releasers increase prepulse inhibition in serotonin 1B knockout mice. Psychopharmacology, 2000, 149(3), 306-312.
106. Dulawa, S. C.; Geyer, M. A. Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology, 2000, 39(11), 2170-2179.
107. Geyer, M. A. Assessing prepulse inhibition of startle in wild-type and knockout mice. Psychopharmacology, 1999, 147(1), 11-13.
108. Tancer, M.; Johanson, C. E. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with damphetamine and mCPP. Drug Alcohol Depend, 2003, 72(1), 33-44.
109. Schenk, S. MDMA Self-administration in laboratory animals: a summary of the literature and proposal for future research. Neuropsychobiology, 2009, 60(3-4), 130-136.
110. Bilsky, E. J.; Hui, Y. Z.; Hubbell, C. L.; Reid, L. D. Methylenedioxymethamphetamines Capacity to Establish Place Preferences and Modify Intake of an Alcoholic Beverage. Pharmacol. Biochem. Behav., 1990, 37(4), 633-638.
111. Robledo, P.; Balerio, G.; Berrendero, F.; Maldonado, R. Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 369(3), 338-349.
112. Trigo, J. M.; Panayi, F.; Soria, G.; Maldonado, R.; Robledo, P. A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology, 2006, 184(2), 212-220.
113. Beardsley, P. M.; Balster, R. L.; Harris, L. S. Self-administration of methylenedioxymethamphetamine (Mdma) by rhesus-monkeys. Drug Alcohol Depend, 1986, 18(2), 149-157.
114. Lamb, R.J.; Griffiths, R.R. Self-injection of D,1-3,4-Methylenedioxymethamphetamine (mdma) in the baboon. Psychopharmacology, 1987, 91(3), 268-272.
115. Fantegrossi, W. E. Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology, 2007, 189(4), 471-482.
116. De La Garza, R.; Fabrizio, K. R.; Gupta, A. Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology, 2007, 189(4), 425-434.
117. Daniela, E.; Brennan, K.; Gittings, D.; Hely, L.; Schenk, S. Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats. Pharmacol. Biochem. Behav., 2004, 77(4), 745-750.
118. Cossu, G.; Ledent, C.; Fattore, L.; Imperato, A.; Bohme, G. A.; Parmentier, M.; Fratta, W. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav. Brain Res., 2001, 118(1), 61-65.
119. Soria, G.; Mendizabal, V.; Touriño, C.; Robledo, P.; Ledent, C.; Parmentier, M.; Maldonado, R.; Valverde, O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology, 2005, 30(9), 1670-1680.
120. Thanos, P. K.; Dimitrakakis, E. S.; Rice, O.; Gifford, A.; Volkow, N. D. Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors. Behav. Brain Res., 2005, 164(2), 206-213.
121. Martin, M.; Ledent, C.; Parmentier, M.; Maldonado, R.; Valverde, O. Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur. J. Neurosci., 2000, 12(11), 4038-4046.
122. Maldonado, R.; Valverde, O.; Berrendero, F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci., 2006, 29(4), 225-232.
123. Robledo, P.; Mendizabal, V.; Ortuno, J.; de la Torre, R.; Kieffer, B. L.; Maldonado, R. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur. J. Neurosci., 2004, 20(3), 853-858.
124. Conductier, G.; Crosson, C.; Hen, R.; Bockaert, J.; Compan, V. 3,4-N-methlenedioxymethamphetamine-induced hypophagia is maintained in 5-HT1B receptor knockout mice, but suppressed by the 5-HT2C receptor antagonist RS102221. Neuropsychopharmacology, 2005, 30(6), 1056-1063.
125. Frith, C. H.; Chang, L. W.; Lattin, D. L.; Walls, R. C.; Hamm, J.; Doblin, R. Toxicity of methylenedioxymethamphetamine (mdma) in the dog and the rat. Fund. Appl. Toxicol., 1987, 9(1), 110-119.
126. Jean, A.; Conductier, G.; Manrique, C.; Bouras, C.; Berta, P.; Hen, R.; Charnay, Y.; Bockaert, J.; Compan, V. Anorexia induced by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the nucleus accumbens. Proc. Natl. Acad. Sci. USA, 2007, 104(41), 16335-16340.
127. Peyron, C.; Faraco, J.; Rogers, W.; Ripley, B.; Overeem, S.; Charnay, Y.; Nevsimalova, S.; Aldrich, M.; Reynolds, D.; Albin, R.; Li, R.; Hungs, M.; Pedrazzoli, M.; Padigaru, M.; Kucherlapati, M.; Fan, J.; Maki, R.; Lammers, G. J.; Bouras, C.; Kucherlapati, R.; Nishino, S.; Mignot, E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med., 2000, 6(9), 991-997.
128. Chemelli, R. M.; Willie, J. T.; Sinton, C. M.; Elmquist, J. K.; Scammell, T.; Lee, C.; Richardson, J. A.; Williams, S. C.; Xiong, Y.; Kisanuki, Y.; Fitch, T. E.; Nakazato, M.; Hammer, R. E.; Saper, C. B.; Yanagisawa, M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 1999, 98(4), 437-451.
129. Mori, T.; Ito, S.; Kuwaki, T.; Yanagisawa, M.; Sakurai, T.; Sawaguchi, T. Monoaminergic neuronal changes in orexin deficient mice. Neuropharmacology, 2010, 58(4-5), 826-832.
130. Vandeputte, C.; Docherty, J.R. Vascular actions of 3,4-methylenedioxymethamphetamine in alpha(2A/D)-adrenoceptor knockout mice. Eur. J. Pharmacol., 2002, 457(1), 45-49.
131. Rajamani, K.; Leong, S.; Lavelle, A.; Docherty, J. R. Prejunctional actions of methylenedioxymethamphetamine in vas deferens from wild-type and alpha(2A/D)-adrenoceptor knockout mice. Eur. J. Pharmacol., 2001, 423(2-3), 223-228.
132. Smits, B. M.; Mudde, J. B.; van de Belt, J.; Verheul, M.; Olivier, J.; Homberg, J.; Guryev, V.; Cools, A. R.; Ellenbroek, B. A.; Plasterk, R. H.; Cuppen, E. Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. Pharmacogenet. Genomics, 2006, 16(3), 159-169.
133. Kalueff, A. V.; Olivier, J. D.; Nonkes, L. J.; Homberg, J. R. Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neurosci. Biobehav. Rev., 2010, 34(3), 373-386.
134. van Boxtel, R.; Toonen, P. W.; Verheul, M.; van Roekel, H. S.; Nijman, I. J.; Guryev, V.; Cuppen, E. Improved generation of rat gene knockouts by target-selected mutagenesis in mismatch repair-deficient animals. BMC Genomics, 2008, 9, 460.
135. Li, P.; Tong, C.; Mehrian-Shai, R.; Jia, L.; Wu, N.; Yan, Y.; Maxson, R. E.; Schulze, E. N.; Song, H.; Hsieh, C. L.; Pera, M. F.; Ying, Q. L. Germline competent embryonic stem cells derived from rat blastocysts. Cell, 2008, 135(7), 1299-1310.
136. Salahpour, A.; Medvedev, I. O.; Beaulieu, J. M.; Gainetdinov, R. R.; Caron, M. G. Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals. Biol. Psychiatry, 2007, 61(1), 65-69.
137. Hommel, J. D.; Sears, R. M.; Georgescu, D.; Simmons, D. L.; DiLeone, R. J. Local gene knockdown in the brain using viralmediated RNA interference. Nat. Med., 2003, 9(12), 1539-1544.